ライフサイエンスコーパス: phentolamine

1 by serotonin were also partially reduced by phentolamine.

2 cking alpha-adrenoreceptors with intravenous phentolamine.

3 of alpha-adrenoreceptor blockade produced by phentolamine.

4 ICI 118,551 but not by the alpha-antagonist phentolamine.

5 o control for any beta-adrenergic effects of phentolamine.

6 rimethaphan also had a depressor response to phentolamine.

7 , and the imidazoline compounds efaroxan and phentolamine.

8 s blocked by the alpha-adrenergic antagonist phentolamine.

9 post-exercise ischaemia after bretylium and phentolamine.

10 of 50, 60, 70, and 80 mm Hg before and after phentolamine (0.5 mg/kg, intravenously, n=7) and propran

11 sympathetic nervous system, rats were given phentolamine (1 mg kg-1, i.v.).

12 (5 mg/kg) and propranolol (1 mg/kg), but not phentolamine (1 mg/kg), significantly antagonized the in

13 uated by prior intravenous administration of phentolamine (1 mg/kg).

14 Topical phentolamine (1 mum) had no effect on resting diameter b

15 n YM, blockade of alpha-adrenoreceptors with phentolamine (1 mum) restored ROV in OM.

16 Tetrodotoxin (TTX, 1 mumol/L), phentolamine (1 mumol/L), prazosin (0.1 mumol/L), or 6-h

17 over study, subjects were given IV saline or phentolamine, 1 mg/kg over 20 min.

18 y antagonized by either the alpha-antagonist phentolamine (10 microM) or the alpha2-antagonist idazox

19 ation), or isoproterenol (1 micromol/L) plus phentolamine (10 micromol/L, selective beta-adrenergic s

20 0(-3) mol/L), propranolol (10(-5) mol/L), or phentolamine (10(-5) mol/L) did not significantly alter

21 Bath application of the octopaminergic drugs phentolamine (10(-6) M), epinastine (10(-6) M) or DCDM (

22 uscle force production, inhibiting alphaARs (phentolamine; 10(-6) m) improved ROV in FA and 1A of old

23 effects of LCN stimulation were reversed by phentolamine (3 microM) or yohimbine (100 nM), but not p

24 Pretreatment with phentolamine (30 microgram/5 microliter, icv, n=8), praz

25 s noradrenaline release) was abolished after phentolamine (40 +/- 3 vs. 2 +/- 1 %; before vs. after b

26 (0.5 mg/kg), but not by the alpha-antagonist phentolamine (5 mg/kg).

27 Phentolamine (75 mg/min) produced vasodilation in obese

28 ne (an alpha(2)-adrenoceptor antagonist) and phentolamine (a non-selective alpha-adrenoceptor antagon

29 at 8 weeks of age were treated with saline, phentolamine, a nonselective alpha-adrenergic receptor a

30 monstrated as a key step in the synthesis of phentolamine, a reversible, nonselective alpha-adrenergi

31 The alpha-adrenoreceptor antagonist phentolamine abolished NE inhibition of eEPSCs.

32 amics in the control limb were unaffected by phentolamine administration in the contralateral (experi

33 Phentolamine (alpha-adrenergic receptor (alpha-Ad) antag

34 Phentolamine (alpha-adrenergic receptor blocker) not onl

35 ividual (prazosin, rauwolscine) or combined (phentolamine) alpha-receptor inhibition.

36 Phentolamine also unmasked the vasodilator AII actions a

37 etylium (to block noradrenaline release) and phentolamine (an alpha-adrenergic antagonist), profound

38 e to catecholamine derived vasoconstriction, phentolamine, an alpha-adrenergic antagonist was adminis

39 such effects can be reduced by therapy with phentolamine, an alpha-adrenergic antagonist.

40 Phentolamine, an alpha-adrenergic blocking agent, preven

41 cine > yohimbine > RX821002 > MK912, whereas phentolamine and idazoxan were essentially neutral antag

42 Pretreatment with phentolamine and nitroglycerine increased transplanted c

43 , bosentan (20 mg/kg/h), or a combination of phentolamine and propranolol (each 1 mg/kg/h), suggestin

44 , bosentan (20 mg/kg/h), or a combination of phentolamine and propranolol (each 1 mg/kg/h), suggestin

45 The findings that phentolamine and propranolol increased plasma leptin con

46 ombined alpha- and beta-adrenergic blockade (phentolamine and propranolol) and after combined alpha-

47 cal alpha+beta adrenergic receptor blockade (phentolamine and propranolol).

48 and beta-adrenergic blockade (intra-arterial phentolamine and propranolol).

49 a-adrenergic and beta-adrenergic antagonists phentolamine and propranolol, or 3) adrenergic blockade

50 tor blockade via intra-arterial infusions of phentolamine and propranolol, respectively.

51 se results indicated the orientation of both phentolamine and WB4101 in the alpha 1-AR binding pocket

52 seen in the alpha 1a-AR for two antagonists, phentolamine and WB4101.

53 -adrenergic (propranolol), alpha-adrenergic (phentolamine and yohimbine), and nitric oxide (NG-monome

54 ased by 21% (P<0.013) and 15% (P=0.004) with phentolamine and yohimbine, respectively.

55 to serotonin (methysergide), norepinephrine (phentolamine) and mu-opiates (naloxone).

56 before and after alpha-receptor inhibition (phentolamine) and then NPY Y1 receptor inhibition (BIBP

57 rol (saline), alpha-adrenoceptor inhibition (phentolamine), and combined alpha- and beta-adrenoceptor

58 ed using iontophoretic delivery of tyramine, phentolamine, and bretylium followed by a norepinephrine

59 nction in OZRs (adrenoreceptor blockade with phentolamine, antioxidant treatment with Tempol and thro

60 ipally by alpha-adrenergic receptors because phentolamine, but not propranolol, augmented the respons

61 utaneous depolarizations were antagonized by phentolamine, but not propranolol.

62 vascular conductance by 49.0 +/- 13.5% after phentolamine (compared to +16.8 +/- 7.0% in the control

63 eatment with the alpha-adrenergic antagonist phentolamine completely prevented loss of TAN, although

64 during 10% hypoxic exercise was greater with phentolamine (Delta306 +/- 43 ml min(-1)) vs. saline (De

65 e premortem cannulation, heparinization, and phentolamine despite current guidance in England to the

66 During hypoxaemia, fetuses treated with phentolamine did not elicit the pronounced femoral vasoc

67 Phentolamine during normoxia produced hypotension, tachy

68 -cholinergic (NANC) nerves with atropine and phentolamine (each 1 microM) were measured in the guinea

69 ery) alpha-adrenergic receptor blockade with phentolamine evoked greater increases in femoral blood f

70 of the alpha-adrenergic receptor antagonist phentolamine for only 30 min.

71 Subsequently, phentolamine further increased FBF to 11.7 +/- 1.6 ml (1

72 cose unclamped + intraportal propranolol and phentolamine hepatic alpha- and beta-adrenergic receptor

73 by the alpha-adrenergic receptor antagonist phentolamine (i.p. and i.t.) but not by the opioid recep

74 fect was abolished when co-administered with phentolamine (i.t.).

75 lol (IA PROP, 25 microg/min), intra-arterial phentolamine (IA PHEN, 12 microg/min per 100 ml forearm

76 milarly, non-selective alpha inhibition with phentolamine increased collateral conductance (242 +/- 5

77 Phentolamine increased the hepatic, splenic, and pulmona

78 Significantly less MA was observed with the phentolamine infusion 10-25 min after capsaicin injectio

79 e on the uninjected foot was seen during the phentolamine infusion compared with the saline infusion,

80 earance was not affected by cold exposure or phentolamine infusion.

81 The fact that phentolamine is an FDA approved non-selective alpha-adre

82 anolol (IV PROP, 80 microg/min), intravenous phentolamine (IV PHEN, 500 microg/min), intra-arterial p

83 e treated with adrenergic receptor blockers (phentolamine, labetalol), a calcium channel blocker (nif

84 Prior administration of phentolamine, labetalol, and nitroglycerine prevented th

85 Animals were treated with phenylephrine, phentolamine, labetalol, and nitroglycerine.

86 This study demonstrates that phentolamine may hold a significant promise in treating

87 o the donor 5 min before aortic cross clamp: phentolamine mesylate (PM) or hydralazine (H).

88 This exploratory study investigated 1.0% phentolamine mesylate ophthalmic solution (PMOS) as a tr

89 ent, 1.8 mL of study drug (containing 0.4 mg phentolamine mesylate or placebo) was injected per cartr

90 esis that local injection of the vasodilator phentolamine mesylate would shorten the duration of soft

91 ntagonist), yohimbine (alpha(2)-antagonist), phentolamine (non-selective alpha-antagonist) and bretyl

92 her the alpha-adrenergic receptor antagonist phentolamine nor the beta2-adrenergic receptor antagonis

93 ) after selective alpha-adrenergic blockade (phentolamine) of one forearm.

94 the lipolytic effect of the alpha-AR blocker phentolamine on adipocytes.

95 effect of alpha(1)-adrenoreceptor blockade (phentolamine) on supine SBP.

96 peated with fetal i.v. treatment with either phentolamine or a V1-receptor antagonist dissolved in sa

97 effects of fetal intravenous treatment with phentolamine or a vasopressinergic V1-receptor antagonis

98 of their corresponding receptor antagonists (phentolamine or methysergide).

99 application of alpha-adrenergic antagonists (phentolamine or phenoxybenzamine) increased spontaneous

100 anglionic action of guanethidine, but not by phentolamine or suramin.

101 ion of antagonists against NE (dibenamine or phentolamine) or ACh (atropine, alpha-bungarotoxin (alph

102 to +16.8 +/- 7.0% in the control arm without phentolamine, P < 0.05).

103 g intra-arterial infusions of normal saline, phentolamine (PHEN) and PHEN with angiotensin II (PHEN+A

104 d) and leg VO2 to intra-arterial infusion of phentolamine (PHEN, alpha-adrenergic antagonist) or phen

105 Phentolamine, prazosin, or tetrodotoxin (1 microM) durin

106 ith the alpha-adrenergic receptor antagonist phentolamine prevented not only the elevation in mRNA le

107 dministered in the presence of bretylium and phentolamine prior to another bout of handgripping, litt

108 ons were not affected by naloxone, atropine, phentolamine, propranolol, methysergide, substance P ant

109 ivity persisted in the presence of atropine, phentolamine, propranolol, tetrodotoxin and Nomega-nitro

110 ine (Delta169 +/- 30 ml min(-1)) or combined phentolamine/propranolol (Delta213 +/- 25 ml min(-1); P

111 - 40 ml min(-1)) but was similar to combined phentolamine/propranolol (Delta450 +/- 43 ml min(-1)).

112 n subjects, administering yohimbine prior to phentolamine resulted in similar findings.

113 ure of BRIN-BD11 cells to either efaroxan or phentolamine selectively inhibited imidazoline-induced i

114 Two centers have used phentolamine to facilitate organ retrieval, with another

115 the extravasated vasopressors: intraosseous phentolamine, topical nitroglycerin ointment, and intraa

116 In the soleus of phentolamine treated animals, we observed the downregula

117 erve crush injury mouse model, we found that phentolamine treatment enhanced motor and functional rec

118 Moreover, phentolamine treatment improved locomotor functional rec

119 Importantly, phentolamine treatment inhibited early signaling events

120 d muscle recovery are integral components of phentolamine treatment-induced global functional recover

121 ntagonist of type A endothelin receptors) or phentolamine (used as a control vasodilator).

122 The phentolamine was well-tolerated and reduced the median d

123 ssessed via nonselective alpha-blockade with phentolamine) was significantly lower in older men.

124 inhibition versus alpha-adrenergic blockade (phentolamine), we found that the CCs accounted for appro

125 Methysergide and phentolamine were equipotent in reversing increases in S

126 histamine, serotonin, thyroid hormones, and phentolamine were without effect.

127 (-1), P<0.004) with propranolol, but neither phentolamine, yohimbine, or L-NMMA altered this response